SSVEP Evaluation of Brain Function (PRO)

Last updated: May 15, 2024
Sponsor: Headsafe MFG
Overall Status: Active - Recruiting

Phase

N/A

Condition

Brain Injury

Neurologic Disorders

Treatment

SSVEP

Clinical Study ID

NCT06013566
2018-10-891-PRO
  • Ages > 12
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The investigational device used in this clinical investigation, the Nurochek PRO System (NCPRO), is a portable electroencephalogram (EEG) headset which delivers a visual stimulus and measures a VEP. The visual stimulus is delivered to the subjects' eyes via light-emitting diodes, and the EEG measures the user's visual-evoked potential. This headset communicates with an application on a computer, which processes the signals and transmits them to a secure cloud server for analysis and storage of the data. Nurochek PRO is a development of the previously FDA cleared Nurochek System.

The primary objective of this clinical investigation was to evaluate the performance of the investigational device (NCPRO) against clinical diagnosis of detection of mild traumatic brain injury (mTBI). The primary endpoint outlined for this study was set at the collection of 100 valid investigational device readings from individuals with concussion and 500 valid investigational device readings from healthy individuals who have had a plausible mechanism of sustaining a concussion, but do not have one. Additionally, readings from healthy individuals are also to be acquired.

The aim of this study was to collect data from 100 readings from individuals with concussion. The initial assumption was that sites would provide players pre-season and make players available for testing post-concussion. In practice, some sites provided player data only post-concussion event (such as medical clinics). Participants were acquired from sporting clubs, medical clinicals and schools.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Individuals aged 12 years and older, participating in sport-related activities.

Exclusion

Exclusion Criteria:

  • Individuals are excluded if they have a history of seizures, history of epilepsy,structural brain injuries, legal blindness, or sensitivity to flashing lights.

Study Design

Total Participants: 1000
Treatment Group(s): 1
Primary Treatment: SSVEP
Phase:
Study Start date:
January 01, 2023
Estimated Completion Date:
January 31, 2026

Connect with a study center

  • Headsafe

    Sydney,
    Australia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.